Chardan Capital Forecasts Strong Price Appreciation for Hyperion DeFi (NASDAQ:HYPD) Stock

Hyperion DeFi (NASDAQ:HYPD) had its price objective upped by investment analysts at Chardan Capital from $7.75 to $8.25 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s price target suggests a potential upside of 136.39% from the stock’s previous close.

A number of other analysts have also issued reports on HYPD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Finally, Cantor Fitzgerald started coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Hyperion DeFi currently has an average rating of “Hold” and a consensus price target of $6.13.

Hyperion DeFi Stock Performance

HYPD opened at $3.49 on Friday. The firm’s fifty day simple moving average is $3.47 and its two-hundred day simple moving average is $5.32. Hyperion DeFi has a 52-week low of $0.85 and a 52-week high of $17.18. The company has a market cap of $28.52 million, a price-to-earnings ratio of -0.86 and a beta of 2.74. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11.

Hyperion DeFi (NASDAQ:HYPD) last released its quarterly earnings results on Thursday, March 26th. The company reported ($7.76) earnings per share for the quarter. The company had revenue of $0.50 million for the quarter. Equities analysts anticipate that Hyperion DeFi will post -41.6 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO David R. Knox bought 27,950 shares of Hyperion DeFi stock in a transaction on Wednesday, December 31st. The shares were bought at an average cost of $3.59 per share, with a total value of $100,340.50. Following the completion of the purchase, the chief financial officer directly owned 327,950 shares of the company’s stock, valued at approximately $1,177,340.50. This trade represents a 9.32% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen R. Strahlman bought 12,112 shares of Hyperion DeFi stock in a transaction on Monday, December 29th. The shares were purchased at an average cost of $3.60 per share, for a total transaction of $43,603.20. Following the completion of the purchase, the director directly owned 91,161 shares of the company’s stock, valued at $328,179.60. This trade represents a 15.32% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 51,918 shares of company stock worth $186,744. Corporate insiders own 10.86% of the company’s stock.

Institutional Trading of Hyperion DeFi

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Formidable Asset Management LLC acquired a new position in Hyperion DeFi in the fourth quarter valued at approximately $83,000. Nations Financial Group Inc. IA ADV purchased a new stake in Hyperion DeFi in the fourth quarter valued at $40,000. Sanctuary Advisors LLC acquired a new position in shares of Hyperion DeFi in the 4th quarter valued at $38,000. Investment House LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter worth $166,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Hyperion DeFi in the 4th quarter valued at approximately $214,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.